Viewing Study NCT03102268


Ignite Creation Date: 2025-12-24 @ 5:42 PM
Ignite Modification Date: 2026-01-24 @ 10:53 PM
Study NCT ID: NCT03102268
Status: UNKNOWN
Last Update Posted: 2017-04-05
First Post: 2017-03-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: ncRNAs in Exosomes of Cholangiocarcinoma
Sponsor: The Second Hospital of Nanjing Medical University
Organization:

Study Overview

Official Title: Exosomes-derived ncRNAs As Biomarkers In Cholangiocarcinoma Patients
Status: UNKNOWN
Status Verified Date: 2017-03
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Exosomes are part of extracellular vesicles(EVs), and can be secreted into the environment by many types of cells. It has been demonstrated that the content and function of exosomes depends on the originating cell and the conditions under which they are produced.Exosomes contain proteins,RNAs and lipid,which may transfer biological information and activities from donor cells to receptor cells. Non-coding RNAs are involved in many biological activities including tumor growth and metastasis.

In this prospective translational study, preclinical and clinical phases have been designed. On the first step, the main goal is to characterize the ncRNAs of cholangiocarcinoma derived exosomes. This exosome biomarker may provide a useful diagnostic tool. As a second step, the study will evaluate the prognostic and predictive value of cholangiocarcinoma exosomes levels in plasma in a prospectively recruited cohort of cholangiocarcinoma patients before and after surgical resection.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: